Ublituximab (LFB-R603, TG-1101, TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1].
Molecular Weight:
(144.18 kDa)
Purity:
98.42
CAS Number:
[1174014-05-1]
Target:
CD20
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted